News
Public · Published
JP Morgan maintains Inspire Medical Systems at Neutral, raises price target to $65 from $60
JP Morgan kept its Neutral rating on Inspire Medical Systems and raised its price target to $65 from $60, an 8.3% increase. That target implies a 3.3% downside from the November 2 close of $67.21.
Published:
Updated:
What happened
JP Morgan kept its Neutral rating on Inspire Medical Systems and raised its price target to $65 from $60, an 8.3% increase. That target implies a 3.3% downside from the November 2 close of $67.21.
Confirmed
Global impact / market context
A Neutral rating means the analyst sees no strong reason to buy or sell. The higher target still sits below the recent share price, so the analyst expects limited upside. Investors can read this as cautious, not bullish, guidance on the stock.
Analyst inference
Five recent analyst notes carry targets from $60 to $76, so views on Inspire are split across firms. One target sits below the last close and others sit above it. That range suggests disagreement about how much growth the company can deliver.
Analyst inference
What to watch
- The other recent notes kept Hold, Equal-Weight, In-Line, Underweight, and Neutral ratings, with targets from $60 to $76, so ratings remain mostly cautious across firms. Confirmed
- Watch whether other firms change their price targets or ratings after this move, since a wider gap between targets and the share price would show shifting analyst views. Proposed
- If the share price stays near its last close while targets sit lower, investors may question growth expectations, and a move toward the target would show the market accepting the cautious view. Analyst inference
Evidence
- Original source link unavailable